Regeneron Pharmaceuticals has received Japanese Ministry of Health,Labour and Welfare(MHLW)approval for its Eylea(aflibercept)injection to treat patients with neovascular age-related macular degeneration(wet AMD)symptoms.
Regeneron chief scientific officer and Regeneron Laboratories president George Yancopoulos said the approval of Eylea in Japan presents new treatment option for wet AMD patients and physicians.
"We are pleased to offer this new therapeutic option,which we hope will decrease the challenges of treatment for wet-AMD patients in Japan,"Yancopoulos added.
The MHLW approval of Eylea is based upon the results of two phase 3 clinical studies,according to the company.
Eylea was approved for wet AMD in the US in November 2011 and in Australia earlier this year.
